Evidence map›Paper›PMID 40750785›Full record

ArticleCell death discovery2025

Heparan sulfate binding protein treatment ameliorates neuropathology and behavioral abnormalities in mucopolysaccharidosis IIIB mice.

Serenella Anzilotti, Melania Scarcella, Mariangela Ciampa, Noemi Di Muraglia, Camilla Anastasio, Chiara Fiorentino, Federica Rossin, Luigi Avallone, Giuseppe Pignataro, Luigi Michele Pavone and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Serenella Anzilotti *Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy.
Melania Scarcella *Department of Molecular Medicine and Medical Biotechnology, Medical School, University of Naples Federico II, Naples, Italy.
Mariangela CiampaDepartment of Molecular Medicine and Medical Biotechnology, Medical School, University of Naples Federico II, Naples, Italy.
Noemi Di MuragliaDivision of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, Medical School, University of Naples Federico II, Naples, Italy.
Camilla AnastasioDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Chiara FiorentinoDepartment of Molecular Medicine and Medical Biotechnology, Medical School, University of Naples Federico II, Naples, Italy.
Federica RossinDepartment of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy.
Luigi AvalloneDepartment of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy.
Giuseppe PignataroDivision of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, Medical School, University of Naples Federico II, Naples, Italy.
Luigi Michele PavoneDepartment of Molecular Medicine and Medical Biotechnology, Medical School, University of Naples Federico II, Naples, Italy. luigimichele.pavone@unina.it.
Valeria De PasqualeDepartment of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy. valeria.depasquale@unina.it.ORCID http://orcid.org/0000-0001-5285-1980

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) CUP E53D23013320006
6 · The paper itself

Abstract

Mucopolysaccharidosis IIIB (MPS IIIB) is a metabolic neurodegenerative disorder caused by a deficiency of the lysosomal enzyme α-N-acetylglucosaminidase (NAGLU), which is involved in the degradation of heparan sulfate (HS). Affected patients exhibit progressive neurodegeneration, behavioral disturbances, and a shortened lifespan. Currently, there is no effective treatment for MPS IIIB. We have recently developed a new therapeutic strategy based on the use of the HS-binding protein NK1, a spliced variant of hepatocyte growth factor. Here, we demonstrate that treating Naglu

Identifiers

PMID40750785
PMCPMC12316897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.